VidPrevtyn Beta, the COVID-19 vaccine developed by Sanofi, has been authorized by the Medicines and Healthcare products Regulatory Agency (MHRA).
It becomes the seventh COVID-19 vaccine authorized by the UK's independent medicines regulator, following expert advice from the government's independent scientific advisory body, the Commission on Human Medicines.
VidPrevtyn Beta combines the spike protein from a COVID virus variant, Beta, with an 'adjuvant' - an additional ingredient designed to trigger a stronger immune response.
The clinical evidence for this authorization is based on data from about 800 individuals previously immunized with an mRNA or viral-vectored vaccine.
The vaccine demonstrated a strong immune response. The most common side effects observed were mild and self-resolved within a few days of vaccination.
The authorization is for the use of this vaccine in those aged 18 and over, as a heterologous booster dose, given as a single injection. This means that those who received a different vaccine (mRNA or viral-vectored) as a primary course, can receive this vaccine as a booster.
As with all vaccines, people with an allergy to one of the components listed in the patient information leaflet should not receive the vaccine.
Research suggests no need for yellow fever vaccine booster after initial dose